News of the week on Fulcrum and CRISPR gene therapy.
Listen now
Description
"Advertising has us chasing cars and clothes, working jobs we hate so we can buy s--- we don't need."  We discuss the publicly available data for the Fulcrum Open Label Extension of the ReDUX4 trial and the recent CRISPR-activation "N-of-one" trial in DMD and what that means for FSHD gene therapy. --- Send in a voice message: https://anchor.fm/peter-l-jones/message
More Episodes
"There's a time for daring and there's a time for caution, and a wise man understands which is called for." Brad our Angry Dad is back with some questions for us on the Avidity FORTITUDE AOC 1020 phase 1/2 trial interim data report and some muscle building. --- Send in a voice message:...
Published 06/22/24
Published 06/22/24
"Whatchyou talkin' 'bout Willis?" In a field where every press release is met with unsubstantiated hoopla and proclamations of BREAKTHROUGH! to fire you up to shake you down, we finally have some real news. We provide our evaluation of Avidity's public interim report on their FORTITUDE AOC-1020...
Published 06/14/24